Cencora | Pharma solutions

In honor of our five-year acquisition anniversary, we’re looking back at the incredible evolution and impact FormularyDecisions has had on formulary review landscape. In this article, our experts share their insights on pivotal shifts in practices, the evolving needs of payers, and how Cencora’s support has driven progress and innovation. Plus, get a glimpse into the future of healthcare decision-making and what trends are on the horizon. https://ow.ly/Wvqo50TQ3KE

At Cencora, we believe in the power of sustainability and community impact. During the BIO International 2024 conference in San Diego, Cencora positioned 180 vibrant banners around town to showcase our commitment to innovation. In an exciting collaboration with Mile High Workshop, we repurposed these banners into stylish tote bags, demonstrating our dedication to environmental stewardship. Mile High WorkShop, a nonprofit dedicated to empowering individuals facing barriers to employment, ensured that our designs were both functional and impactful. This partnership not only reduces waste but also supports a powerful mission that fosters meaningful change. Together, we are united in our responsibility to create a healthier, greener future! 💚♻️

Due to the Inflation Reduction Act’s Part D benefit redesign, the Medicare Part D market will experience a seismic shift in 2025. As a refresher, Part D plans will face a significantly higher financial liability as patients now have a $2,000 out-of-pocket cap; policy observers and patient organizations were concerned that with Part D plans having limited levers to pull, patients may face greater access restrictions and limited plan availability as a result. Cencora’s pharma consulting team’s analysis of the Part D landscape and formulary files validates the expected impacts. Read on for highlights from our analysis — and much more in today’s edition of Health Policy Weekly.

Serving our customers is one of our highest priorities. Recently, team members from our Consumer Products team stepped up in an urgent situation to support a mother and her child in delivering a device they desperately needed. Read the story: https://ow.ly/9SWT50TsxlM

There’s less than 3 weeks to go until BIO-Europe! We're looking forward to connecting with you at the conference. In the meantime, we invite you to join our webinar on October 30, 2024, specially designed for BIO-Europe attendees. Led by Sandra Anderson, Senior Vice President of International Commercialization at Cencora, this panel will explore the complexities of launching biopharmaceutical products in European markets. Hear from industry leaders Jacob Liawatidewi, Executive Vice President at Amphastar Pharmaceuticals; Jan Van Acker, strategic advisor in healthcare and biopharmaceuticals; and Kevin McDermott, Vice President of International Commercialization at Cencora, as they share insights on navigating regulatory challenges and optimizing market entry strategies. Don’t miss this chance to gain actionable strategies and best practices for success in the evolving pharmaceutical landscape! Register now! https://ow.ly/ffHO50TPIZX #BIOEurope #BIOEurope2024

A customized channel strategy is crucial to overcoming access challenges, especially during banner-launch planning. It ensures optimal product access by aligning distribution with product attributes and patient needs while preventing roadblocks. Whether it’s a first launch or a new therapeutic area, channel strategies accelerate time to market and improve patient and provider experiences. Read the article for expert insights: https://ow.ly/qN3k50TPIQQ

If you're a manufacturer outsourcing field support, it may not be immediately obvious what types of experience and expertise are most essential to build your team. We’ve compiled resources to help you select the best outsourced field team. Download our checklist ➡️ https://ow.ly/O7cq50TPIGc

With the November general election approaching, stakeholders in the healthcare sector should be informed about the potential policy shifts. Cencora invites you to an informative webinar, on Thursday, October 31, with Corey Ford , VP Reimbursement and Policy Insights. In addition to answering questions from the audience, Corey will discuss how the election outcomes could impact key federal programs like the Affordable Care Act (ACA) and the Inflation Reduction Act (IRA). Join us to learn more about: - The potential impact of election results on health policy - Scenarios based on presidential and congressional outcomes - Insights into the future of major federal programs - Strategic guidance for navigating post-election changes - Expert analysis on the evolving healthcare landscape Register now to prepare for the upcoming changes: https://ow.ly/YIwG50TPIfz #HealthPolicy #USElections #Election2024 #InflationReductionAct #AffordableCareAct

According to the National Community Pharmacists Association, what percentage of independent pharmacies may not sell Part D prescription drugs negotiated under the Medicare Drug Price Negotiation Program, due to the final guidance that “fails to ensure fair reimbursement for pharmacies that dispense the drugs” and “fails to ensure timely reimbursement”? If you guessed more than half, you’re starting to get warm. Find out exactly how high that percentage is, and access NCPA’s full report on its fall survey of independent pharmacy owners and managers, in our Policy by Numbers feature in today’s Health Policy Weekly.

Discover our recent double-blind survey on the Inflation Reduction Act's impact on Medicare Part D plans. Conducted this past spring, it features insights from 41 advisors across national and regional health plans, integrated delivery networks, and pharmacy benefit managers. Get the infographic to learn more ➡️ https://ow.ly/kGjy50TOvqF #Medicare #InflationReductionAct